MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtct.2024.03.030

Медицинская библиотека · Transplantation and cellular therapy · 2024

The Adverse Event Landscape of Stem Cell Transplant: Evidence for AGVHD Driving Early Transplant Associated Toxicities.

Takahashi Takuto, Watkins Benjamin, Bratrude Brandi, Neuberg Donna, Hebert Kyle, Betz Kayla, Yu Alison, Choi Sung W, Davis Jeffrey, Duncan Christine, Giller Roger, Grimley Michael, Harris Andrew C, Jacobsohn David, Lalefar Nahal, Farhadfar Nosha, Pulsipher Michael A, Shenoy Shalini, Petrovic Aleksandra, Schultz Kirk R, Yanik Gregory A, Blazar Bruce R, Horan John T, Langston Amelia, Kean Leslie S, Qayed Muna

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

Although unrelated-donor (URD) hematopoietic cell transplantation (HCT) is associated with many toxicities, a detailed analysis of adverse events, as defined by the Common Terminology Criteria for Adverse Events (CTCAE), has not previously been curated. This represents a major unmet need, especially as it relates to assessing the safety of novel agents. We analyzed a detailed AE database from the "ABA2" randomized, double-blind, placebo-controlled clinical trial of abatacept for acute graft-versus-host disease (AGVHD) prevention, for which the FDA mandated a detailed AE assessment through Day +180, and weekly neutrophil and platelet counts through Day +100. These were analyzed for their relationship to key transplant outcomes, with a major focus on the impact of AGVHD on the development/severity of AEs. A total of 2102 AEs and 1816 neutrophil/platelet counts were analyzed from 142 8/8-HLA-matched URD HCT recipients on ABA2 (placebo cohort, n = 69, abatacept cohort, n = 73). This analysis resulted in 2 major observations. (1) Among graft source, conditioning intensity, age, and Grade 2 to 4 AGVHD, only AGVHD impacted Grade 3 to 5 AE acquisition after the first month post-transplant. (2) The development of Grade 3 to 4 AGVHD was associated with thrombocytopenia. We have created a detailed resource for the transplant community by which to contextualize clinical toxicities after transplant. It has identified AGVHD as a major driver of post-HCT Grade 3 to 5 AEs, and underscored a link between AGVHD and thrombocytopenia. This establishes a critical safety framework upon which the impact of novel post-transplant AGVHD therapeutics should be evaluated. This trial was registered at www.clinicaltrials.gov (#NCT01743131).

Для цитирования: Takahashi Takuto, Watkins Benjamin, Bratrude Brandi, Neuberg Donna, Hebert Kyle, Betz Kayla, Yu Alison, Choi Sung W, Davis Jeffrey, Duncan Christine, Giller Roger, Grimley Michael, Harris Andrew C, Jacobsohn David, Lalefar Nahal, Farhadfar Nosha, Pulsipher Michael A, Shenoy Shalini, Petrovic Aleksandra, Schultz Kirk R, Yanik Gregory A, Blazar Bruce R, Horan John T, Langston Amelia, Kean Leslie S, Qayed Muna. The Adverse Event Landscape of Stem Cell Transplant: Evidence for AGVHD Driving Early Transplant Associated Toxicities.. Transplantation and cellular therapy. 2024. DOI: 10.1016/j.jtct.2024.03.030.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.